AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29957886 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 85
Study 29957886 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 85
Study 28012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (6 μg)
Number of subjects: 75
Study 28012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (10 μg)
Number of subjects: 75
Study 28012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (15 μg)
Number of subjects: 75
Study 28012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR (20 μg)
Number of subjects: 75
Study 28012819 — intervention group
Group type: COMPARATOR
Intervention: Topical bimatoprost 0.03%
Number of subjects: 75
Study 28012819 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Number of subjects: 75
Study 28012819 — intervention group
Group type: COMPARATOR
Intervention: Topical bimatoprost
Number of subjects: 75
Study 26497960 — intervention group
Group type: COMPARATOR
Intervention: Diesel exhaust (DE) exposure for 2 hours with a particulate matter concentration of 300 μg/m(3)
Number of subjects: 18
Study 26497960 — intervention group
Group type: COMPARATOR
Intervention: Ambient air (AA) exposure for 2 hours
Number of subjects: 18
Study 23578679 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with significant disability progression (SDP) at 5 years
Number of subjects: 180
Study 23578679 — intervention group
Group type: COMPARATOR
Intervention: Patients without significant disability progression (SDP) at 5 years
Number of subjects: 180
Study 21317176 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheltered biopsy forceps
Number of subjects: 27
Study 21317176 — intervention group
Group type: COMPARATOR
Intervention: Standard unsheathed biopsy forceps
Number of subjects: 27
Study 19528562 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice, 1800 mg twice daily for 24 weeks
Number of subjects: 62
Study 19528562 — intervention group
Group type: COMPARATOR
Intervention: Placebo, twice daily for 24 weeks
Number of subjects: 62
Study 17530404 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Controlled Trial (RCT) design for evaluating sexual offender treatment
Number of subjects: 0
Study 17530404 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT study by Marques et al.
Number of subjects: 0
Study 17530404 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative strategies for evaluating treatment
Number of subjects: 0
Study 17151968 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (500 ml of 30% dextrose solution, containing 100 IU insulin and 80 mEq of potassium, at a rate of 1 ml x kg (‐1) x h (‐1))
Number of subjects: 49
Study 17151968 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (control group)
Number of subjects: 49
Study 14615106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cannabis extract (n=211)
Number of subjects: 667
Study 14615106 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta9-tetrahydrocannabinol (Delta9-THC; n=206)
Number of subjects: 667
Study 14615106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=213)
Number of subjects: 667
Study 14615106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported spasticity and pain
Number of subjects: 667
Study 10338218 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured triglycerides
Number of subjects: 19
Study 10338218 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 19
Study 7856528 — intervention group
Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 30
Study 7856528 — intervention group
Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 30
Study 2392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (1 mg/kg)
Number of subjects: 2
Study 2392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (2 mg/kg)
Number of subjects: 2
Study 2392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 2
Study 2392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 2
Study 2392497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2392497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (various doses)
Number of subjects: 2
Study 6453240 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation therapy
Number of subjects: 95
Study 6453240 — intervention group
Group type: COMPARATOR
Intervention: Soft-tissue massage
Number of subjects: 95
Study 31954707 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled radiologic examination orders
Number of subjects: 700
Study 29784521 — intervention group
Group type: EXPERIMENTAL
Intervention: Health worker involvement in disclosure process
Number of subjects: 73
Study 29784521 — intervention group
Group type: EXPERIMENTAL
Intervention: Differences in training and involvement in disclosure process among health worker categories
Number of subjects: 73
Study 27749511 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive neurally adjusted ventilatory assist
Number of subjects: 18
Study 25708251 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart phone application (SPA) instructions, n=108
Number of subjects: 260
Study 25708251 — intervention group
Group type: COMPARATOR
Intervention: Written instructions with visual aids (control group), n=152
Number of subjects: 260
Study 23527361 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD/CAM surgical guides
Number of subjects: 10
Study 23527361 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical guides
Number of subjects: 10
Study 20538669 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-and-shoot (SAS) mode (n=50)
Number of subjects: 100
Study 20538669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pitch mode (n=50)
Number of subjects: 100
Study 19018915 — intervention group
Group type: EXPERIMENTAL
Intervention: TTT intervention (educational train-the-trainer course plus pharmacotherapy feedback)
Number of subjects: 168
Study 19018915 — intervention group
Group type: COMPARATOR
Intervention: Standard education (control group)
Number of subjects: 168
Study 15958039 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO therapy
Number of subjects: 29
Study 15958039 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 29
Study 12938567 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry data
Number of subjects: 0
Study 12938567 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza patients
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients without limitations to activity
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-bound inpatients
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients with pneumonia
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients without pneumonia
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients who died within 9 months of the onset of influenza
Number of subjects: 0
Study 10481405 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients who were alive 9 months after influenza infection
Number of subjects: 0
Study 10481405 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8602180 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) per day
Number of subjects: 18314
Study 8602180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18314
Study 1943090 — intervention group
Group type: EXPERIMENTAL
Intervention: rHGH (0.2 mg/kg.d)
Number of subjects: 13
Study 1943090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk alone
Number of subjects: 91
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk with supplemental vitamin D
Number of subjects: 91
Study 7113949 — intervention group
Group type: COMPARATOR
Intervention: Similac
Number of subjects: 91
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: Male infants
Number of subjects: 91
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactating mothers
Number of subjects: 91
Study 7113949 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of lactation
Number of subjects: 91
Study 30702971 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy
Number of subjects: 156
Study 30702971 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib with neoadjuvant chemotherapy in PTGS2-low group (n = 100)
Number of subjects: 156
Study 30702971 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib use
Number of subjects: 156
Study 30702971 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib in addition to docetaxel
Number of subjects: 156
Study 30702971 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib in CALGB 30801 trial
Number of subjects: 156
Study 28476567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (soluble fiber and protein)
Number of subjects: 98
Study 28476567 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake (glycemic index, monounsaturated fat, polyunsaturated fat)
Number of subjects: 98
Study 28476567 — intervention group
Group type: COMPARATOR
Intervention: Total daily insulin dose per kilogram
Number of subjects: 98
Study 25872531 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow fever (YF) vaccination
Number of subjects: 0
Study 25872531 — intervention group
Group type: EXPERIMENTAL
Intervention: Innate immune response characterization
Number of subjects: 0
Study 23645323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril monotherapy
Number of subjects: 38
Study 23645323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (34% of children)
Number of subjects: 38
Study 21432712 — intervention group
Group type: EXPERIMENTAL
Intervention: Toilet advertisement
Number of subjects: 200
Study 21432712 — intervention group
Group type: COMPARATOR
Intervention: Rubbish advertisement
Number of subjects: 200
Study 19751151 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed gB infection
Number of subjects: 239
Study 19751151 — intervention group
Group type: COMPARATOR
Intervention: Single genotype infection
Number of subjects: 239
Study 19751151 — intervention group
Group type: COMPARATOR
Intervention: gB genotype
Number of subjects: 239
Study 17715115 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MRI
Number of subjects: 115
Study 15023093 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating Disorder Diagnostic Scale (HDDS)
Number of subjects: 0
Study 11262466 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 4589
Study 11262466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4589
Study 9037342 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home educational intervention conducted by lay health workers (LHWs)
Number of subjects: 321
Study 9037342 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 321
Study 7507308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck incision (44 unilateral, 60 bilateral)
Number of subjects: 104
Study 7507308 — intervention group
Group type: COMPARATOR
Intervention: Bladder neck incision (unilateral)
Number of subjects: 104
Study 7507308 — intervention group
Group type: COMPARATOR
Intervention: Bladder neck incision (bilateral)
Number of subjects: 104
Study 7507308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder neck incision
Number of subjects: 104
Study 3090583 — intervention group
Group type: EXPERIMENTAL
Intervention: A + N (alcohol and nicotine)
Number of subjects: 24
Study 3090583 — intervention group
Group type: COMPARATOR
Intervention: A + O (alcohol and smoking placebo)
Number of subjects: 24
Study 3090583 — intervention group
Group type: COMPARATOR
Intervention: O + N (Nicotine and placebo drink)
Number of subjects: 24
Study 3090583 — intervention group
Group type: COMPARATOR
Intervention: O + O (no drugs)
Number of subjects: 24
Study 30348630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile videoconferencing intervention for 4 weeks
Number of subjects: 81
Study 30348630 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person intervention for 4 weeks
Number of subjects: 81
Study 30348630 — intervention group
Group type: COMPARATOR
Intervention: Self-care intervention for 4 weeks
Number of subjects: 81
Study 27250845 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel‐200
Number of subjects: 379
Study 27250845 — intervention group
Group type: COMPARATOR
Intervention: PBS
Number of subjects: 379
Study 25040148 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐Communicating Children's Pain Checklist Postoperative Version (NCCPC‐PV)
Number of subjects: 40
Study 25040148 — intervention group
Group type: EXPERIMENTAL
Intervention: Echelle Douleur Enfant San Salvador (DESS)
Number of subjects: 40
Study 25040148 — intervention group
Group type: COMPARATOR
Intervention: Children's Hospital of Eastern Ontario Pain Scale (CHEOPS)
Number of subjects: 40
Study 21890335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide/Formoterol 320/9 μg bid (CIC/F)
Number of subjects: 160
Study 21890335 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol 250/50 μg bid (FP/S)
Number of subjects: 160
Study 20528697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1 W, 10 Hz, 100 mJ, 1064 nm) and EMP
Number of subjects: 21
Study 20528697 — intervention group
Group type: COMPARATOR
Intervention: EMP alone (control)
Number of subjects: 21
Study 18541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard vaccination schedule (0, 1, 6 months)
Number of subjects: 1964
Study 18541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccination schedule (0, 1, 2 months)
Number of subjects: 1964
Study 18541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination at screening
Number of subjects: 1964
Study 18541174 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly discounted vaccine from local health departments
Number of subjects: 1964
Study 15805900 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 1015
Study 15805900 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1015
Study 12867685 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 74
Study 12867685 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 74
Study 12867685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 74
Study 11086369 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione 100 mg/d for 7 days
Number of subjects: 41
Study 11086369 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstenedione 300 mg/d for 7 days
Number of subjects: 41
Study 11086369 — intervention group
Group type: COMPARATOR
Intervention: No androstenedione (control group)
Number of subjects: 41
Study 11086369 — intervention group
Group type: EXPERIMENTAL
Intervention: 19‐norandrostenedione 10 microg
Number of subjects: 41
Study 8956447 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-package (direct mailing) consisting of consensus recommendations, headline questions with answers, and classification of oestrogens available in Norway.
Number of subjects: 374
Study 8956447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information-package).
Number of subjects: 374
Study 1552034 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (57 +/- 7 mg/day)
Number of subjects: 14
Study 1552034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1552034 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 14
Study 2863089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam (3 to 9 mg per day)
Number of subjects: 671
Study 2863089 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (1 to 3 mg per day)
Number of subjects: 671
Study 2863089 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam
Number of subjects: 671
Study 2863089 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 671
Study 30456414 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified supine Double-S position
Number of subjects: 0
Study 30456414 — intervention group
Group type: COMPARATOR
Intervention: Standard prone position
Number of subjects: 0
Study 31742648 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (20 hours)
Number of subjects: 59
Study 31742648 — intervention group
Group type: COMPARATOR
Intervention: Activity-based attention training
Number of subjects: 59
Study 29133798 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and feedback of urine cotinine
Number of subjects: 58
Study 29133798 — intervention group
Group type: COMPARATOR
Intervention: Control group (measurements only: questionnaires, urine cotinine, lung function)
Number of subjects: 58
Study 25995238 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based, nurse-led vascular risk factor management programme
Number of subjects: 330
Study 25995238 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 330
Study 23306647 — intervention group
Group type: COMPARATOR
Intervention: B/YP
Number of subjects: 46
Study 23306647 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 46
Study 23306647 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT III
Number of subjects: 46
Study 23306647 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT
Number of subjects: 46
Study 21646262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor-only training
Number of subjects: 89
Study 21646262 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated defibrillator feedback only
Number of subjects: 89
Study 21646262 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructor training combined with automated feedback
Number of subjects: 89
Study 21646262 — intervention group
Group type: COMPARATOR
Intervention: Control (no structured training)
Number of subjects: 89
Study 18653575 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 39
Study 18653575 — intervention group
Group type: COMPARATOR
Intervention: Other protease inhibitors (Control)
Number of subjects: 39
Study 16771937 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Number of subjects: 722
Study 16771937 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori test-and-eradicate
Number of subjects: 722
Study 16771937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PPI and H. pylori testing
Number of subjects: 722
Study 16771937 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 722
Study 16771937 — intervention group
Group type: COMPARATOR
Intervention: Empirical antisecretory therapy (PPI)
Number of subjects: 722
Study 15539531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain communication intervention (viewing a pain management and pain communication film)
Number of subjects: 0
Study 15539531 — intervention group
Group type: COMPARATOR
Intervention: Pain management film only (control group)
Number of subjects: 0
Study 15539531 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 0
Study 11157639 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic agents
Number of subjects: 0
Study 9270646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia during cardiopulmonary bypass
Number of subjects: 99
Study 9270646 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermia during cardiopulmonary bypass
Number of subjects: 99
Study 7879621 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochemical method using six biotinylated lectins to detect carbohydrates in the endolymphatic sac.
Number of subjects: 15
Study 7879621 — intervention group
Group type: EXPERIMENTAL
Intervention: Histochemical method to detect protein in the endolymphatic sac.
Number of subjects: 15
Study 3366521 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill running (215 m.min‐1 for 10,000 footstrikes at -6%)
Number of subjects: 14
Study 3366521 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running (215 m.min‐1 for 10,000 footstrikes at +6%)
Number of subjects: 14
Study 3366521 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill running (both downhill and uphill)
Number of subjects: 14
Study 3366521 — intervention group
Group type: COMPARATOR
Intervention: Resting control procedure
Number of subjects: 14
Study 2166209 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 0
Study 2166209 — intervention group
Group type: EXPERIMENTAL
Intervention: CY 216 (once daily)
Number of subjects: 0
Study 2166209 — intervention group
Group type: EXPERIMENTAL
Intervention: PK 10169
Number of subjects: 0
Study 2166209 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 10172 and KABI 2165
Number of subjects: 0
Study 2166209 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 0
Study 2166209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4811950 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy for 12 weeks
Number of subjects: 30
Study 4811950 — intervention group
Group type: EXPERIMENTAL
Intervention: Social therapy for 12 weeks
Number of subjects: 30
Study 4811950 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31857298 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention targeting patients with negative BCx
Number of subjects: 0
Study 31857298 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 28187400 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram plus placebo (SSRI monotherapy)
Number of subjects: 106